SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016)
SELLAS Life Sciences (SLS) posted quarterly Convertible Debt of $7.4 million for Q4 2016, up 636.8% quarter-over-quarter from $1.0 million in Q1 2012.
SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Convertible Debt for 2 consecutive years, with $7.4 million the latest figure, recorded in Q4 2016.
- In Q4 2016, Convertible Debt changed N/A year-over-year to $7.4 million; the TTM figure through Dec 2016 stood at $7.4 million (changed N/A YoY), while the FY2016 annual figure was $7.4 million, changed N/A from the prior year.
- Convertible Debt climbed to $7.4 million in Q4 2016 per SLS's latest filing, from $1.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $7.4 million in Q4 2016 and bottomed at $1.0 million in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 7.37 Mn |
| Mar 31, 2012 | 1.00 Mn |